H.C. Wainwright analyst Sean Lee CFA reiterated a Buy rating on Verastem (VSTM) today and set a price target of $3.00. The company’s shares closed last Thursday at $2.37.
According to TipRanks.com, CFA is a 5-star analyst with an average return of 67.3% and a 68.3% success rate. CFA covers the Healthcare sector, focusing on stocks such as ThermoGenesis Holdings, CASI Pharmaceuticals, and Kazia Therapeutics.
Verastem has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See today’s analyst top recommended stocks >>
Based on Verastem’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $78.65 million and net profit of $13.14 million. In comparison, last year the company earned revenue of $9.03 million and had a GAAP net loss of $30.14 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
